4-甲基-3-(4,4,5,5-四甲基-[1,3,2]二噁硼烷-2-基)苯甲酸 | 515131-35-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-甲基-3-(4,4,5,5-四甲基-[1,3,2]二噁硼烷-2-基)苯甲酸
• 中文别名: 5-羧-2-甲基苯基硼酸频哪醇酯
• 英文名称: 4-methyl-3-(4,4,5,5-tetramethyl[1,3,2]dioxaborolan-2-yl)benzoic acid
• 英文别名: 4-Methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic acid
• CAS: 515131-35-8
• 化学式: C₁₄H₁₉BO₄
• 分子量: 262.113
• InChiKey: SUZCHODXFJYVKA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.99
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  55.8
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2934999090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  2-8°C

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 5-Carboxy-2-methylphenylboronic acid, pinacol ester
Synonyms: 4-Methyl-3-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)benzoic acid

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 5-Carboxy-2-methylphenylboronic acid, pinacol ester
CAS number: 515131-35-8

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C14H19BO4
Molecular weight: 262.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-甲基-3-(4,4,5,5-四甲基-[1,3,2]二噁硼烷-2-基)苯甲酸 在 四(三苯基膦)钯 potassium carbonate 作用下， 以 乙二醇二甲醚 、 二氯甲烷 、 水 为溶剂， 反应 0.58h， 生成 3-[2-[3(diethylamino)propyl]amino-8-(2,6-difluorophenyl)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-4-yl]-4-methylbenzoic acid
  参考文献：
  名称：

  WO2007/147103

  摘要：

  公开号：
• 作为产物：
  描述：

  3-碘-4-甲基苯甲酸 、 联硼酸频那醇酯 在 1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 potassium acetate 作用下， 以 DMF (N,N-dimethyl-formamide) 为溶剂， 反应 21.0h， 生成 4-甲基-3-(4,4,5,5-四甲基-[1,3,2]二噁硼烷-2-基)苯甲酸
  参考文献：
  名称：

  [EN] FUSED HETEROARYL DERIVATIVES FOR USE AS P38 KINASE INHIBITORS IN THE TREATMENT OF I.A. RHEUMATOID ARTHRISTIS
  [FR] DERIVES HETEROARYLE CONDENSES UTILISABLES COMME INHIBITEURS DE KINASE P38, NOTAMMENT DANS LE TRAITEMENT DE POLYARTHRITE RHUMATOIDE

  摘要：

  式(I)的化合物：其中A是一个5-成员杂环芳基环，是p38激酶的抑制剂，可用于治疗由p38激酶活性介导的疾病或疾病状态，或由p38活性产生的细胞因子介导的疾病状态，如类风湿性关节炎。

  公开号：

  WO2004010995A1
• 作为试剂：
  描述：

  3-碘-4-甲基苯甲酸 、 联硼酸频那醇酯 、 potassium acetate 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 氮气 、 N,N-二甲基甲酰胺 、 sodium hydroxide 、 乙酸乙酯 、 4-甲基-3-(4,4,5,5-四甲基-[1,3,2]二噁硼烷-2-基)苯甲酸 、 水 作用下， 反应 32.0h， 以to provide 4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic acid的产率得到4-甲基-3-(4,4,5,5-四甲基-[1,3,2]二噁硼烷-2-基)苯甲酸
  参考文献：
  名称：

  Aryl nitrogen-containing bicyclic compounds and methods of use

  摘要：

  本发明涉及一种新的化合物类别，对蛋白激酶介导的疾病，包括炎症、癌症和相关疾病的预防和治疗有用。该化合物具有一般的式子I，其中A1、A2、A3、B、R1、R2、R3和R4在此定义。因此，本发明还涉及包含本发明化合物的制药组合物，使用本发明化合物和组合物预防和治疗激酶介导的疾病的方法，以及用于制备本发明化合物的中间体和过程。

  公开号：

  US20070054916A1

文献信息

• [EN] BCR-ABL TYROSINE-KINASE LIGANDS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME<br/>[FR] LIGANDS DE TYROSINE-KINASE BCR-ABL CAPABLES DE SE DIMÉRISER DANS UNE SOLUTION AQUEUSE, ET PROCÉDÉS D'UTILISATION DE CEUX-CI
  申请人：COFERON INC

  公开号：WO2015106292A1

  公开（公告）日：2015-07-16

  Described herein are monomers capable of forming a biologically useful multimer when in contact with one, two, three or more other monomers in an aqueous media. In one aspect, such monomers may be capable of binding to another monomer in an aqueous media (e.g. invivo) to form a multimer (e.g. a dimer). Contemplated monomers may include a ligand moiety, a linker element, and a connector element that joins the ligand moiety and the linker element. In an aqueous media, such contemplated monomers may join together via each linker element and may thus be capable of modulating one or more biomolecules substantially simultaneously, e.g., modulate two or more binding sites on a Bcr-Abl tyrosine kinase.

  本文描述了一种单体，当与水性介质中的另一个、两个、三个或更多其他单体接触时，能够形成生物学上有用的多聚体。在一个方面，这种单体可能能够在水性介质（例如体内）中与另一个单体结合以形成多聚体（例如二聚体）。考虑到的单体可能包括配体基团、连接元素和连接配体基团与连接元素的连接元素。在水性介质中，这些考虑到的单体可以通过每个连接元素结合在一起，因此可以同时调节一个或多个生物分子，例如，调节Bcr-Abl酪氨酸激酶上的两个或更多结合位点。
• Discovery and optimization of a series of 3-substituted indazole derivatives as multi-target kinase inhibitors for the treatment of lung squamous cell carcinoma
  作者：Qi Wang、Yang Dai、Yinchun Ji、Huanyu Shi、Zuhao Guo、Danqi Chen、Yuelei Chen、Xia Peng、Yinglei Gao、Xin Wang、Lin Chen、Yuchen Jiang、Meiyu Geng、Jingkang Shen、Jing Ai、Bing Xiong

  DOI：10.1016/j.ejmech.2018.12.015

  日期：2019.2

  lung squamous cell carcinoma to design multi-target inhibitors represents a potential strategy for the medical treatment. In this study, through screening an in-house focused library, we identified an interesting indazole scaffold. And following with binding analysis, we elaborated the structure-activity relationship of this hit compound by optimizing four parts guided by the DDR2 enzymatic assay, which

  尽管肺腺癌患者受益于靶向治疗的发展，但肺鳞癌（SqCC）患者由于该疾病的复杂性和异质性而无法有效治疗。因此，基于对肺鳞状细胞癌突变的遗传分析以设计多靶点抑制剂代表了一种潜在的治疗策略。在这项研究中，通过筛选内部聚焦库，我们确定了一种有趣的吲唑支架。然后进行结合分析，我们通过优化DDR2酶测定法指导的四个部分，详细阐述了这种命中化合物的结构-活性关系，从而得到了有效的先导化合物10a。。我们进一步优化了针对肺鳞状细胞癌中两个重要激酶FGFR1和DDR2的双重酶促抑制作用。最后，从细胞抗增殖活性测试和体内药代动力学测试中，发现3-取代的吲唑衍生物11k是很有前途的候选者，并通过小鼠异种移植模型进行了体内药理学研究，证明了其强大的抗肿瘤功效。额外的体外药物样评估进一步证明了化合物11k对于SqCC药物开发可能是有价值的。
• [EN] HEPATITIS C INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE L'HÉPATITE C ET LEURS UTILISATIONS
  申请人：ABBOTT LAB

  公开号：WO2012087833A1

  公开（公告）日：2012-06-28

  This disclosure relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.

  这份披露涉及：(a) 抑制HCV等化合物及其盐；(b) 用于制备这些化合物和盐的中间体；(c) 包含这些化合物和盐的组合物；(d) 制备这些中间体、化合物、盐和组合物的方法；(e) 使用这些化合物、盐和组合物的方法；以及(f) 包含这些化合物、盐和组合物的试剂盒。
• New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors
  申请人：Laboratorios Almirall, S.A.

  公开号：EP2108641A1

  公开（公告）日：2009-10-14

  This invention is directed to new inhibitors of the p38 mitogen-activated protein kinase having the general formula (I) to processes for their preparation; to pharmaceutical compositions comprising them; and to their use in therapy.

  这项发明涉及具有一般式(I)的新p38丝裂原活化蛋白激酶抑制剂；其制备方法；包含它们的药物组合物；以及它们在治疗中的应用。
• Multigram Synthesis of BMS-929075, an Allosteric, Palm Site Inhibitor of HCV NS5B Replicase, Involving the Synthesis of a Highly Functionalized Benzofuran through a Telescoped Process
  作者：Daniel Smith、Subramaniam Krishnananthan、Nicholas A. Meanwell、Arvind Mathur、Jianqing Li

  DOI：10.1021/acs.oprd.0c00198

  日期：2020.6.19

  formation of the highly functionalized benzofuran core 26 through a chromatography-free, telescoped process that proceeds via acylation and a subsequent concomitant demethylation and Boc deprotection using BBr3, followed by an acid-catalyzed cyclization from Boc-protected 2-(3-bromo-2-fluoro-6-methoxyphenyl)-N-methylacetamide 23. This process was applied to the preparation of 110 g of high-quality

  有效的按比例放大合成4-氟-2-（4-氟苯基）-N-甲基-5-（2-甲基-5-（1-（嘧啶-2-基）环丙基氨基甲酰基）苯基）苯并呋喃-3-描述了羧酰胺（BMS-929075），其是HCV NS5B复制酶的变构，手掌部位抑制剂。该方法的重点包括（a ）由区域特异性锂化的1-溴-2-氟代铜（2-）介导的一锅合成2-（3-溴-2-氟-6-甲氧基苯基）乙酸（21）。 4-甲氧基苯（13）和2-溴乙酸乙酯（18）；（b）形成高度官能化的苯并呋喃核26通过无色谱的伸缩工艺进行，该工艺通过酰化以及随后伴随的脱甲基化和使用BBr 3的Boc脱保护进行，然后由Boc保护的2-（3-溴-2-氟-6-甲氧基苯基）进行酸催化环化- ñ甲基乙酰胺23。此过程用于制备110 g高质量BMS-929075，以进行临床前毒理学研究。